Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02219126
Other study ID # MILK
Secondary ID
Status Completed
Phase N/A
First received August 14, 2014
Last updated January 12, 2018
Start date August 2014
Est. completion date January 1, 2018

Study information

Verified date January 2018
Source University of Turku
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to investigate differences in digestion rates and stomach problems caused by pasteurized and homogenized milk compared with raw milk in healthy adults by ingestible capsule that measures pH and pressure, diary of symptoms, blood glucose and triacylglycerol levels and plasma cytokine levels.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date January 1, 2018
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Homogenized and pasteurized milk causes stomach problems (self-reported)

- unhomogenized and unpasteurized milk does not cause stomach problems (self-reported)

- age 18-65

- BMI 18,5 - 30

- hemoglobin under normal range

- fasting plasma alanine aminotransferase ALAT < 60 U/l (normal liver function)

- fasting plasma thyroid-stimulating hormone (TSH) 0.4 - 4.5 mU/l (normal thyroid function)

- fasting plasma creatinine < 118 umol/l (normal kidney function)

Exclusion Criteria:

- pace maker

- Crohn's disease or other disease of the intestinal tract

- intestinal operation within the last 3 months

- difficult dysphagia

- smoking

- constipation

Study Design


Related Conditions & MeSH terms

  • Unidentified Stomach Discomfort Following Dairy Consumption

Intervention

Other:
Dietary intervention


Locations

Country Name City State
Finland Department of Biochemistry University of Turku Turku

Sponsors (1)

Lead Sponsor Collaborator
University of Turku

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pressure in the intestinal tract Pressure in the intestinal tract as measured by ingestible Smart Pill -capsule. Day 0 - Day 5
Primary Gastrointestinal symptoms (self-reported) Gastrointestinal symptoms (self-reported) as measured by a questionnaire. The questionnaire is devided into seven types of stomach discomfort, and also includes a possibility to describe a stomach discomfort outside these seven given alternatives. The severity of the symptoms is self-reported on a three-step scale. Day 0 - Day 5
Secondary Plasma triacylglycerols 20min, 40min, 60min, 120min, 180min, 240min
Secondary Plasma glucose 20min, 40min, 60min, 90min, 120min, 180min, 240min
Secondary Plasma triacylglycerols 20min, 40min, 60min, 90min, 120min, 180min, 240min
Secondary Plasma insulin 20min, 40min, 60min, 90min, 120min, 180min, 240min